The amyloid state and its association with protein misfolding diseases

Nature Reviews Molecular Cell Biology

Volumn 15, Issue 6, 2014, Pages 384-396

  Knowles, Tuomas P J ^a   Vendruscolo, Michele ^a   Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; OLIGOMER; PEPTIDES AND PROTEINS; SYNUCLEIN;

CONFORMATIONAL TRANSITION; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; PROTEIN HOMEOSTASIS; PROTEIN STRUCTURE; REVIEW;

ALZHEIMER DISEASE; AMYLOID; AMYLOIDOSIS; ANIMALS; HUMANS; PROTEIN CONFORMATION; PROTEIN FOLDING;

EID: 84901355639     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/nrm3810     Document Type: Review

References (180)

1. Dobson, C. M. Protein folding and misfolding. Nature 426, 884-890 (2003). (Pubitemid 38056880)
2. Hardy, J. & Selkoe, D. J. Medicine - the amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297, 353-356 (2002). (Pubitemid 34790756)
3. Balch, W. E., Morimoto, R. I., Dillin, A. & Kelly, J. W. Adapting proteostasis for disease intervention. Science 319, 916-919 (2008). (Pubitemid 351263754)
4. Tanaka, M., Collins, S. R., Toyama, B. H. & Weissman, J. S. The physical basis of how prion conformations determine strain phenotypes. Nature 442, 585-589 (2006). (Pubitemid 44167919)
5. Chiti, F. & Dobson, C. M. Protein misfolding, functional amyloid, and human disease. Annu. Rev. Bioch. 75, 333-366 (2006). (Pubitemid 44118036)
6. Knowles, T. P. J. & Buehler, M. J. Nanomechanics of functional and pathological amyloid materials. Nature Nanotech. 6, 469-479 (2011).
7. Haass, C. & Selkoe, D. J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nature Rev. Mol. Cell. Biol. 8, 101-112 (2007). (Pubitemid 46432529)
8. Eisenberg, D. & Jucker, M. The amyloid state of proteins in human diseases. Cell 148, 1188-1203 (2012).
9. Ballard, C. et al. Alzheimer's disease. Lancet 377, 1019-1031 (2011).
10. Querfurth, H. W. & LaFerla, F. M. Mechanisms of disease Alzheimer's disease. N. Engl. J. Med. 362, 329-344 (2010).
11. Kim, Y. E., Hipp, M. S., Bracher, A., Hayer-Hartl, M. & Ulrich Hartl, F. Molecular chaperone functions in protein folding and proteostasis. Annu. Rev. Bioch. 82, 323-355 (2013).
12. Alzheimer's disease international. World Alzheimer report (2010).
13. Dementia: A public health priority. World health organization and Alzheimer's disease international (2012).
14. Olshansky, S. J. et al. A potential decline in life expectancy in the united states in the 21st century. N. Engl. J. Med. 352, 1138-1145 (2005). (Pubitemid 40365358)
15. Alzheimer's disease: Facts and figures. Alzheimer's association (2012).
16. Walsh, D. M. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002). (Pubitemid 34288854)
17. Cremades, N. et al. Direct observation of the interconversion of normal and toxic forms of α-synuclein. Cell 149, 1048-1059 (2012).
18. Cohen, S. I. A. et al. Proliferation of amyloid-β 42 aggregates occurs through a secondary nucleation mechanism. Proc. Natl Acad. Sci. USA 110, 9758-9763 (2013).
19. Lesne, S. et al. A specific amyloid-β protein assembly in the brain impairs memory. Nature 440, 352-357 (2006).
20. Campioni, S. et al. A causative link between the structure of aberrant protein oligomers and their toxicity. Nature Chem. Biol. 6, 140-147 (2010).
21. Bucciantini, M. et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511 (2002). (Pubitemid 34288846)
22. Caughey, B. & Lansbury, P. T. Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci. 26, 267-298 (2003). (Pubitemid 37064935)
23. Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L. & La Ferla, F. M. Intraneuronal a β causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688 (2005). (Pubitemid 40320703)
24. Winner, B. et al. In vivo demonstration that α-synuclein oligomers are toxic. Proc. Natl Acad. Sci. USA 108, 4194-4199 (2011).
25. Koffie, R. M. et al. Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl Acad. Sci. USA 106, 4012-4017 (2009).
26. Dobson, C. M. Protein misfolding, evolution and disease. Trends Bioch. Sci. 24, 329-332 (1999). (Pubitemid 29421804)
27. Greenwald, J. & Riek, R. On the possible amyloid origin of protein folds. J. Mol. Biol. 421, 417-426 (2012).
28. Carny, O. & Gazit, E. A model for the role of short self-assembled peptides in the very early stages of the origin of life. FASEB J. 19, 1051-1055 (2005). (Pubitemid 40946429)
29. De Pas, W. H. & Chapman, M. R. Microbial manipulation of the amyloid fold. Res. Microbiol. 163, 592-606 (2012).
30. Fowler, D. M., Koulov, A. V., Balch, W. E. & Kelly, J. W. Functional amyloid - from bacteria to humans. Trends Bioch. Sci. 32, 217-224 (2007). (Pubitemid 46694328)
31. Fandrich, M. & Dobson, C. M. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J. 21, 5682-5690 (2002). (Pubitemid 35315268)
32. Knowles, T. P. J. et al. Observation of spatial propagation of amyloid assembly from single nuclei. Proc. Natl Acad. Sci. USA 108, 14746-14751 (2011).
33. Astbury, W. T., Dickinson, S. & Bailey, K. The X-ray interpretation of denaturation and the structure of the seed globulins. Biochem. J. 29, 2351-2360 (1935).
34. Kendrew, J. C. et al. 3-dimensional model of the myoglobin molecule obtained by X-ray analysis. Nature 181, 662-666 (1958).
35. Berman, H. M. et al. The protein data bank. Nucl. Acids Res. 28, 235-242 (2000). (Pubitemid 30047768)
36. Rosenbaum, D. M., Rasmussen, S. G. F. & Kobilka, B. K. The structure and function of g-protein-coupled receptors. Nature 459, 356-363 (2009).
37. Anfinsen, C. B. Principles that govern folding of protein chains. Science 181, 223-230 (1973).
38. Dill, K. A. & Chan, H. S. From Levinthal to pathways to funnels. Nature Struct. Biol. 4, 10-19 (1997). (Pubitemid 27020916)
39. Onuchic, J. N., Luthey-Schulten, Z. & Wolynes, P. G. Theory of protein folding: the energy landscape perspective. Annu. Rev. Phys. Chem. 48, 545-600 (1997). (Pubitemid 127443918)
40. Dobson, C. M., Sali, A. & Karplus, M. Protein folding: a perspective from theory and experiment. Angew. Chem. Int. Ed. 37, 868-893 (1998). (Pubitemid 28228882)
41. Baldwin, A. J. et al. Metastability of native proteins and the phenomenon of amyloid formation. J. Am. Chem. Soc. 133, 14160-14163 (2011).
42. Gazit, E. The "correctly folded" state of proteins: is it a metastable state. Angew. Chem. Int. Ed. 41, 257-259 (2002). (Pubitemid 34118066)
43. Vendruscolo, M., Knowles, T. P. J. & Dobson, C. M. Protein solubility and protein homeostasis: A generic view of protein misfolding disorders. Cold Spring Harb. Perspect. Biol. 3, a010454 (2011).
44. Wolff, S., Weissman, J. S. & Dillin, A. Differential scales of protein quality control. Cell 157, 52-64 (2014).
45. Dyson, H. J. & Wright, P. E. Intrinsically unstructured proteins and their functions. Nature Rev. Mol. Cell Biol. 6, 197-208 (2005). (Pubitemid 40314921)
46. Uversky, V. N. & Dunker, A. K. Understanding protein non-folding. Biochim. Biophys. Acta 1804, 1231-1264 (2010).
47. Dedmon, M. M., Lindorff-Larsen, K., Christodoulou, J., Vendruscolo, M. & Dobson, C. M. Mapping long-range interactions in α-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J. Am. Chem. Soc. 127, 476-477 (2005). (Pubitemid 40174345)
48. Hou, L. M. et al. Solution NMR studies of the Aβ(1-40) and Aβ(1-42) peptides establish that the Met35 oxidation state affects the mechanism of amyloid formation. J. Am. Chem. Soc. 126, 1992-2005 (2004).
49. Varadi, M. et al. pE-DB: A database of structural ensembles of intrinsically disordered and of unfolded proteins. Nucl. Acids Res. 42, D326-D335 (2014).
50. Tartaglia, G. G. et al. Prediction of aggregation-prone regions in structured proteins. J. Mol. Biol. 380, 425-436 (2008).
51. Polymeropoulos, M. H. et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047 (1997). (Pubitemid 27443610)
52. Spillantini, M. G. et al. α-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
53. Westermark, P. et al. Amyloid fibrils in human insulinoma and islets of langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc. Natl Acad. Sci. USA 84, 3881-3885 (1987). (Pubitemid 17088383)
54. Waudby, C. A., Launay, H., Cabrita, L. D. & Christodoulou, J. Protein folding on the ribosome studied using NMR spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 74, 57-75 (2013).
55. Chiti, F. & Dobson, C. M. Amyloid formation by globular proteins under native conditions. Nature Chem. Biol. 5, 15-22 (2009).
56. Kelly, J. W. The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101-106 (1998). (Pubitemid 28107921)
57. Vendruscolo, M. & Dobson, C. M. Structural biology: protein self-assembly intermediates. Nature Chem. Biol. 9, 216-217 (2013).
58. Neupert, W. & Herrmann, J. M. Translocation of proteins into mitochondria. Annu. Rev. Bioch. 76, 723-749 (2007).
59. Chacinska, A., Koehler, C. M., Milenkovic, D., Lithgow, T. & Pfanner, N. Importing mitochondrial proteins: machineries and mechanisms. Cell 138, 628-644 (2009).
60. Meinema, A. C. et al. Long unfolded linkers facilitate membrane protein import through the nuclear pore complex. Science 333, 90-93 (2011).
61. Park, S. H. et al. PolyQ proteins interfere with nuclear degradation of cytosolic proteins by sequestering the Sis1p chaperone. Cell 154, 134-145 (2013).
62. Fletcher, D. A. & Mullins, D. Cell mechanics and the cytoskeleton. Nature 463, 485-492 (2010).
63. Omenetto, F. G. & Kaplan, D. L. New opportunities for an ancient material. Science 329, 528-531 (2010).
64. Anderson, V. J. & Lekkerkerker, H. N. W. Insights into phase transition kinetics from colloid science. Nature 416, 811-815 (2002). (Pubitemid 34453731)
65. Prusiner, S. B. Prions. Proc. Natl Acad. Sci. USA 95, 13363-13383 (1998). (Pubitemid 28525623)
66. Serio, T. R. et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. Science 289, 1317-1321 (2000). (Pubitemid 30656041)
67. Sipe, J. D. & Cohen, A. S. Review: History of the amyloid fibril. J. Struct. Biol. 130, 88-98 (2000).
68. Buxbaum, J. N. & Linke, R. P. A molecular history of the amyloidoses. J. Mol. Biol. 421, 142-159 (2012).
69. Stefani, M. & Dobson, C. M. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J. Mol. Med. 81, 678-699 (2003). (Pubitemid 37491594)
70. Liao, L. et al. Proteomic characterization of postmortem amyloid plaques isolated by laser capture microdissection. J. Biol. Chem. 279, 37061-37068 (2004). (Pubitemid 39129056)
71. Wang, Q. et al. Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J. 19, 869-871 (2005). (Pubitemid 40617412)
72. Xia, Q. et al. Proteomic identification of novel proteins associated with lewy bodies. Front. Biosci. 13, 3850-3856 (2008). (Pubitemid 351594664)
73. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997). (Pubitemid 27488813)
74. Sawaya, M. R. et al. Atomic structures of amyloid cross-β spines reveal varied steric zippers. Nature 447, 453-457 (2007). (Pubitemid 46816731)
75. Fitzpatrick, A. W. P. et al. Atomic structure and hierarchical assembly of a cross-β amyloid fibril. Proc. Natl Acad. Sci. USA 110, 5468-5473 (2013).
76. Petkova, A. T. et al. A structural model for Alzheimer's β-amyloid fibrils based on experimental constraints from solid state NMR. Proc. Natl Acad. Sci. USA 99, 16742-16747 (2002). (Pubitemid 36034043)
77. Wasmer, C. et al. Amyloid fibrils of the HET-s(218-289) prion form a β solenoid with a triangular hydrophobic core. Science 319, 1523-1526 (2008). (Pubitemid 351398180)
78. Luhrs, T. et al. 3D structure of Alzheimer's amyloid-β(1-42) fibrils. Proc. Natl Acad. Sci. USA 102, 17342-17347 (2005).
79. Guijarro, J. I., Sunde, M., Jones, J. A., Campbell, I. D. & Dobson, C. M. Amyloid fibril formation by an SH3 domain. Proc. Natl Acad. Sci. USA 95, 4224-4228 (1998). (Pubitemid 28207893)
80. Chiti, F. et al. Designing conditions for In vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA 96, 3590-3594 (1999). (Pubitemid 29168954)
81. Urbanc, B. et al. In silico study of amyloid β-protein folding and oligomerization. Proc. Natl Acad. Sci. USA 101, 17345-17350 (2004). (Pubitemid 39657406)
82. Auer, S., Meersman, F., Dobson, C. M. & Vendruscolo, M. A generic mechanism of emergence of amyloid protofilaments from disordered oligomeric aggregates. PLoS Comp. Biol. 4, e1000222 (2008).
83. Tycko, R. Solid-state NMR studies of amyloid fibril structure. Annu. Rev. Phys. Chem. 62, 279-299 (2011).
84. Jimenez, J. L. et al. The protofilament structure of insulin amyloid fibrils. Proc. Natl Acad. Sci. USA 99, 9196-9201 (2002). (Pubitemid 34764590)
85. Sachse, C., Fandrich, M. & Grigorieff, N. Paired beta-sheet structure of an Aβ(1-40) amyloid fibril revealed by electron microscopy. Proc. Natl Acad. Sci. USA 105, 7462-7466 (2008). (Pubitemid 351830040)
86. Knowles, T. P. et al. Role of intermolecular forces in defining material properties of protein nanofibrils. Science 318, 1900-1903 (2007).
87. Krishnan, R. & Lindquist, S. L. Structural insights into a yeast prion illuminate nucleation and strain diversity. Nature 435, 765-772 (2005). (Pubitemid 40839721)
88. Collinge, J. & Clarke, A. R. A general model of prion strains and their pathogenicity. Science 318, 930-936 (2007). (Pubitemid 350098981)
89. Halfmann, R., Alberti, S. & Lindquist, S. Prions, protein homeostasis, and phenotypic diversity. Trends Cell Biol. 20, 125-133 (2010).
90. Wright, C. F., Teichmann, S. A., Clarke, J. & Dobson, C. M. The importance of sequence diversity in the aggregation and evolution of proteins. Nature 438, 878-881 (2005). (Pubitemid 41753072)
91. Knowles, T. P. J. et al. Twisting transition between crystalline and fibrillar phases of aggregated peptides. Phys. Rev. Lett. 109, 158101 (2012).
92. Smith, J. F., Knowles, T. P. J., Dobson, C. M., MacPhee, C. E. & Welland, M. E. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl Acad. Sci. USA 103, 15806-15811 (2006). (Pubitemid 44657548)
93. Tartaglia, G. G., Pechmann, S., Dobson, C. M. & Vendruscolo, M. Life on the edge: a link between gene expression levels and aggregation rates of human proteins. Trends Bioch. Sci. 32, 204-206 (2007). (Pubitemid 46694330)
94. Apetri, M. M., Maiti, N. C., Zagorski, M. G., Carey, P. R. & Anderson, V. E. Secondary structure of α -synuclein oligomers: characterization by Raman and atomic force microscopy. J. Mol. Biol. 355, 63-71 (2006). (Pubitemid 41774139)
95. Nettleton, E. J. et al. Characterization of the oligomeric states of insulin in self-assembly and amyloid fibril formation by mass spectrometry. Bioph. J. 79, 1053-1065 (2000). (Pubitemid 30626196)
96. 2-microglobulin amyloid assembly revealed by ion mobility spectrometry-mass spectrometry. Proc. Natl Acad. Sci. USA 107, 6794-6798 (2010).
97. Bernstein, S. L. et al. Amyloid-β protein oligomerization and the importance of tetramers and dodecamers in the aetiology of Alzheimer's disease. Nature Chem. 1, 326-331 (2009).
98. 1-40 peptide. Nature Struct. Mol. Biol. 19, 79-83 (2012).
99. Cohen, S. I. A., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. J. From macroscopic measurements to microscopic mechanisms of protein aggregation. J. Mol. Biol. 421, 160-171 (2012).
100. Knowles, T. P. J. et al. An analytical solution to the kinetics of breakable filament assembly. Science 326, 1533-1537 (2009).
101. ten Wolde, P.R. & Frenkel, D. Enhancement of protein crystal nucleation by critical density fluctuations. Science 277, 1975-1978 (1997). (Pubitemid 27449135)
102. Nelson, R. et al. Structure of the cross-β spine of amyloid-like fibrils. Nature 435, 773-778 (2005). (Pubitemid 40839722)
103. Jucker, M. & Walker, L. C. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532-540 (2011).
104. Fandrich, M. Absolute correlation between lag time and growth rate in the spontaneous formation of several amyloid-like aggregates and fibrils. J. Mol. Biol. 365, 1266-1270 (2007). (Pubitemid 46048846)
105. Collins, S. R., Douglass, A., Vale, R. D. & Weissman, J. S. Mechanism of prion propagation: amyloid growth occurs by monomer addition. PLoS Biol. 2, 1582-1590 (2004).
106. Bolognesi, B. et al. Single point mutations induce a switch in the molecular mechanism of the aggregation of the Alzheimer's disease associated Aβ42 peptide. ACS Chem. Biol. 9, 378-382 (2013).
107. Meier, M. et al. Plug-based microfluidics with defined surface chemistry to miniaturize and control aggregation of amyloidogenic peptides. Angew. Chem. Int. Ed. 121, 1515-1517 (2009).
108. Lee, S. J., Desplats, P., Sigurdson, C., Tsigelny, I. & Masliah, E. Cell-to-cell transmission of non-prion protein aggregates. Nature Rev. Neurol. 6, 702-706 (2010).
109. Polymenidou, M. & Cleveland, D. W. The seeds of neurodegeneration: prion-like spreading in als. Cell 147, 498-508 (2011).
110. Cohen, S. et al. Spatial propagation of protein polymerization. Phys. Rev. Lett. 112, 098101 (2014).
111. Aguzzi, A. Cell biology: Beyond the prion principle. Nature 459, 924-925 (2009).
112. Aguzzi, A. & Rajendran, L. The transcellular spread of cytosolic amyloids, prions, and prionoids. Neuron 64, 783-790 (2009).
113. Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45-51 (2013).
114. Walker, L. C., Diamond, M. I., Duff, K. E. & Hyman, B. T. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 70, 304-310 (2013).
115. Maji, S. K. et al. Functional amyloids as natural storage of peptide hormones in pituitary secretory granules. Science 325, 328-332 (2009).
116. Chiti, F., Stefani, M., Taddei, N., Ramponi, G. & Dobson, C. M. Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature 424, 805-808 (2003). (Pubitemid 37021713)
117. Dubay, K. F. et al. Prediction of the absolute aggregation rates of amyloidogenic polypeptide chains. J. Mol. Biol. 341, 1317-1326 (2004).
118. Fernandez-Escamilla, A. M., Rousseau, F., Schymkowitz, J. & Serrano, L. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nature Biotech. 22, 1302-1306 (2004). (Pubitemid 39336784)
119. Pawar, A. P. et al. Prediction of "aggregation-prone" and "aggregation-susceptible" regions in proteins associated with neurodegenerative diseases. J. Mol. Biol. 350, 379-392 (2005). (Pubitemid 40805470)
120. Neudecker, P. et al. Structure of an intermediate state in protein folding and aggregation. Science 336, 362-366 (2012).
121. Broome, B. M. & Hecht, M. H. Nature disfavors sequences of alternating polar and non-polar amino acids: Implications for amyloidogenesis. J. Mol. Biol. 296, 961-968 (2000).
122. Richardson, J. S. & Richardson, D. C. Natural β-sheet proteins use negative design to avoid edge-to-edge aggregation. Proc. Natl Acad. Sci. USA 99, 2754-2759 (2002). (Pubitemid 34240533)
123. Otzen, D. E. & Oliveberg, M. Salt-induced detour through compact regions of the protein folding landscape. Proc. Natl Acad. Sci. USA 96, 11746-11751 (1999). (Pubitemid 29502803)
124. Kaganovich, D., Kopito, R. & Frydman, J. Misfolded proteins partition between two distinct quality control compartments. Nature 454, 1088-1095 (2008).
125. Tyedmers, J., Mogk, A. & Bukau, B. Cellular strategies for controlling protein aggregation. Nature Rev. Mol. Cell. Biol. 11, 777-788 (2010).
126. Bence, N. F., Sampat, R. M. & Kopito, R. R. Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555 (2001). (Pubitemid 32493425)
127. Ross, C. A. & Poirier, M. A. Protein aggregation and neurodegenerative disease. Nature Med. 10, S10-S17 (2004). (Pubitemid 38901862)
128. Glickman, M. H. & Ciechanover, A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev. 82, 373-428 (2002). (Pubitemid 34654457)
129. Rubinsztein, D. C. The roles of intracellular protein-degradation pathways in neurodegeneration. Nature 443, 780-786 (2006). (Pubitemid 44622682)
130. Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N. & Rubinsztein, D. C. α-synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem. 278, 25009-25013 (2003). (Pubitemid 37548663)
131. Mizushima, N., Levine, B., Cuervo, A. M. & Klionsky, D. J. Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075 (2008). (Pubitemid 351317450)
132. Morimoto, R. I. Regulation of the heat shock transcriptional response: Cross talk between a family of heat shock factors, molecular chaperones, and negative regulators. Genes Dev. 12, 3788-3796 (1998). (Pubitemid 29024840)
133. Jiang, Q. et al. ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693 (2008).
134. Knowles, T. P. J. et al. Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proc. Natl Acad. Sci. USA 104, 10016-10021 (2007). (Pubitemid 47175255)
135. Xu, L. Q. et al. Influence of specific Hsp70 domains on fibril formation of the yeast prion protein Ure2. Philos. Trans. R. Soc. B 368, 20110410 (2013).
136. Wilson, M. R. & Easterbrook-Smith, S. B. Clusterin is a secreted mammalian chaperone. Trends Bioch. Sci. 25, 95-98 (2000). (Pubitemid 30122416)
137. Harold, D. et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genet. 41, 1088-1093 (2009).
138. Lambert, J.-C. et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genet. 45, 1452-1458 (2013).
139. Lambert, J. C. et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genet. 41, 1094-1099 (2009).
140. Tomic, J. L., Pensalfini, A., Head, E. & Glabe, C. G. Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 35, 352-358 (2009).
141. Shankar, G. M. et al. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (2007). (Pubitemid 46438992)
142. Palop, J. J. & Mucke, L. Amyloid-β-induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks. Nature Neurosci. 13, 812-818 (2010).
143. Feany, M. B. & Bender, W. W. A Drosophila model of Parkinson's disease. Nature 404, 394-398 (2000). (Pubitemid 30164341)
144. Luheshi, L. M., Crowther, D. C. & Dobson, C. M. Protein misfolding and disease: from the test tube to the organism. Curr. Opin. Chem. Biol. 12, 25-31 (2008).
145. Bilen, J. & Bonini, N. M. Drosophila as a model for human neurodegenerative disease. Annu. Rev. Genet. 39, 153-171 (2005). (Pubitemid 43011111)
146. Ben-Zvi, A., Miller, E. A. & Morimoto, R. I. Collapse of proteostasis represents an early molecular event in caenorhabditis elegans aging. Proc. Natl Acad. Sci. USA 106, 14914-14919 (2009).
147. Kaminksi Schierle, G. S. et al. In situ measurements of the formation and morphology of intracellular β-amyloid fibrils by super-resolution fluorescence imaging. J. Am. Chem. Soc. 133, 12902-12905 (2011).
148. McGuire, E. K. et al. Selenium-enhanced electron microscopic imaging of different aggregate forms of a segment of the amyloid beta peptide in cells. ACS Nano 6, 4740-4747 (2012).
149. Ries, J. et al. Superresolution imaging of amyloid fibrils with binding-activated probes. ACS Chem. Neurosci. 4, 1057-1061 (2013).
150. Lansbury, P. T. & Lashuel, H. A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 443, 774-779 (2006). (Pubitemid 44622681)
151. Karran, E., Mercken, M. & De Strooper, B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature Rev. Drug Discov. 10, 698-712 (2011).
152. Lue, L. F. et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853-862 (1999).
153. Baglioni, S. et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 26, 8160-8167 (2006). (Pubitemid 44315140)
154. Cheon, M. et al. Structural reorganisation and potential toxicity of oligomeric species formed during the assembly of amyloid fibrils. PLoS Comp. Biol. 3, 1727-1738 (2007). (Pubitemid 47502977)
155. Bolognesi, B. et al. ANS binding reveals common features of cytotoxic amyloid species. ACS Chem. Biol. 5, 735-740 (2010).
156. Olzscha, H. et al. Amyloid-like aggregates sequester numerous metastable proteins with essential cellular functions. Cell 144, 67-78 (2011).
157. Narayan, P. et al. Single molecule characterization of the interactions between amyloid-β peptides and the membranes of hippocampal cells. J. Am. Chem. Soc. 135, 1491-1498 (2013).
158. Ciryam, P., Tartaglia, G. G., Morimoto, R. I., Dobson, C. M. & Vendruscolo, M. Widespread aggregation and neurodegenerative diseases are associated with supersaturated proteins. Cell Rep. 5, 781-790 (2013).
159. David, D. C. et al. Widespread protein aggregation as an inherent part of aging in C. elegans. PLoS Biol. 8, e1000450 (2010).
160. Gidalevitz, T., Ben-Zvi, A., Ho, K. H., Brignull, H. R. & Morimoto, R. I. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 311, 1471-1474 (2006). (Pubitemid 43376703)
161. Koga, H., Kaushik, S. & Cuervo, A. M. Protein homeostasis and aging: the importance of exquisite quality control. Ageing Res. Rev. 10, 205-215 (2011).
162. Reis-Rodrigues, P. et al. Proteomic analysis of age-dependent changes in protein solubility identifies genes that modulate lifespan. Aging Cell 11, 120-127 (2012).
163. Cooper-Knock, J. et al. Gene expression profiling in human neurodegenerative disease. Nature Rev. Neurol. 8, 518-530 (2012).
164. Blalock, E. M. et al. Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc. Natl Acad. Sci. USA 101, 2173-2178 (2004). (Pubitemid 38229034)
165. Dobson, M. The story of medicine (Quercus, 2013).
166. Dobson, C. M. In the footsteps of alchemists. Science 304, 1259-1262 (2004). (Pubitemid 38697410)
167. Johnson, S. M. et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc. Chem. Res. 38, 911-921 (2005).
168. Razavi, H. et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. Int. Ed. 42, 2758-2761 (2003). (Pubitemid 36807218)
169. Bulawa, C. E. et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA 109, 9629-9634 (2012).
170. Uversky, V. N. Intrinsically disordered proteins and novel strategies for drug discovery. Expert Opin. Drug Discov. 7, 475-488 (2012).
171. Tóth, G. et al. Targeting the intrinsically disordered structural ensemble of α-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PLoS ONE 9, e87133 (2014).
172. Arosio, P., Vendruscolo, M., Dobson, C. M. & Knowles, T. P. Chemical kinetics for drug discovery to combat protein aggregation diseases. Trends Pharmacol. Sci. 35, 127-135 (2014).
173. Baigent, C. et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
174. Fersht, A. R. Structure and mechanism in protein science: A guide to enzyme catalysis and protein folding (W. H. Freeman, 1999).
175. De Strooper, B., Vassar, R. & Golde, T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nature Rev. Neurol. 6, 99-107 (2010).
176. Dumoulin, M. & Dobson, C. M. Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie 86, 589-600 (2004). (Pubitemid 39535630)
177. Hard, T. & Lendel, C. Inhibition of amyloid formation. J. Mol. Biol. 421, 441-465 (2012).
178. Luheshi, L. M. et al. Sequestration of the Aβ peptide prevents toxicity and promotes degradation in vivo. PLoS Biol. 8, e1000334 (2010).
179. Schenk, D. Amyloid-β immunotherapy for Alzheimer's disease: The end of the beginning. Nature Rev. Neurosci. 3, 824-828 (2002). (Pubitemid 135706694)
180. Schenk, D., Basi, G. S. & Pangalos, M. N. Treatment strategies targeting amyloid β-protein. Cold Spring Harb. Perspect. Med. 2, a006387 (2012).